Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
上海復宏生物爲中國纖維化藥物臨床研究中的第一位患者注射劑量
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。